Now that we’ve gone over the pharmacology of the GLP-1 agonists, let’s get back to the economics.

Last time, we asked - how will the economy handle a $12,000/year drug that everyone wants?

Now we have an answer: the compounding loophole.

https://www.astralcodexten.com/p/the-compounding-loophole